John Snisarenko - 09 Jan 2022 Form 4 Insider Report for Oyster Point Pharma, Inc.

Reporting relationship: Chief Commercial Officer
Issuer ticker: N/A
Reported as of: 09 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jan 2022, 18:47:50 UTC
Prior SEC filing: 04 Nov 2021
Next SEC filing: 06 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Brandon Fenn, Attorney-in-Fact

Key filing fact

John Snisarenko filed Form 4 for Oyster Point Pharma, Inc. on 11 Jan 2022.

Key facts

This page summarizes John Snisarenko's Form 4 filing for Oyster Point Pharma, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Jan 2022, 18:47.

Change

Previous filing in this sequence was filed on 04 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OYST transaction

Common Stock

Award

Transaction value: $0
Shares: +12,100
Change %: +66%
Price: $0.000000
Shares after: 30,322
Date: 09 Jan 2022
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OYST transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +54,500
Change %
Price: $0.000000
Shares after: 54,500
Date: 09 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 54,500
Exercise price: $16.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Footnote F2

25% of the RSUs vest on January 7, 2023 and the remainder vest annually thereafter, in equal amounts, on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date.

Footnote F3

Options granted on January 9, 2022 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 7, 2023 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date.